CAMBRIA-2: Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant [AZD9833, a Next-Generation, Oral Selective Estrogen Receptor Degrader] Versus Standard Endocrine Therapy [Aromatase Inhibitor or Tamoxifen] as Adjuvant Treatment for Patients with ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (NCT05952557)
CAMBRIA-2
This trial is Currently recruiting
Registration number NCT05952557
Program & service
This trial is being run with the Cancer service, and as part of the Medical Oncology program.
Trial phase
Phase 3
Trial participation type
This trial has been designed for the Clinical Research of a Drug.
Principal investigator
Dr Maggie Moore
More information
To find out more about this clinical trial, please review full details on the ANZCTR website.
View on ANZCTRIf you would like further details or have any questions about this clinical trial, we encourage you to get in touch with us and a member of our team will be happy to provide you with more information.